The $450 Million Annuity to 43 States

Sandoz - a company spun off from Novartis three years ago - has agreed to pay 43 US states and territories $400 million over seven years starting in 2027, plus an additional payment of approximately $50 million to states that settled earlier, for a total of approximately $450 million for antitrust conduct that ended seven years ago, when Sandoz was still a Novartis subsidiary.

That is a settlement with a time warp. The company writing the check does not exist under the same corporate structure as the one that caused the problem. The money starts flowing in 2027. The alleged conduct wrapped up in 2019. And nobody, in this particular round, had to admit wrongdoing.

The basic point is that this is not a scandal at this stage. It is a billing cycle. The generic drug antitrust enforcement apparatus has become a serial settlement machine, where each category of plaintiff - the feds, direct purchasers, end purchasers, states, indirect resellers - gets its own tranche, on its own schedule, with its own legal language. Sandoz today announced the last big one. When it closes, only opt-out individual plaintiffs will remain.

To see how this works, you have to look at the payment terms, not the press release. The $450 million breaks into $400 million going to 43 states and territories over seven years starting in 2027, plus roughly $50 million going to states that settled earlier in this round - a catch-up payment that the settlement agreement requires. There is also a separate $28.5 million deal with indirect reseller plaintiffs, which covers pharmacies, clinics, and hospitals that resold drugs to consumers.

Seven-year payment schedules are a feature, not an accident. They turn what is nominally a penalty into something closer to a structured obligation. Sandoz spreads the hit across its post-spin-off cash flow. The states get payment certainty from a company that is now publicly traded on the Swiss Exchange, rather than holding a claim against a subsidiary of a much larger parent. And the "no admission of wrongdoing" language that appears in the press release is standard for civil settlements - it is not a mystery clause, it is the default setting.

The earlier rounds had more bite. In March 2020, the DOJ secured a $195 million criminal penalty - the largest ever for a domestic antitrust case at the time - and Sandoz admitted to conspiring with competitors to fix prices, allocate customers, and rig bids on generic drugs. The drugs included things like clobetasol cream, tobramycin inhalation solution, and benazepril HCTZ. That admission was part of a deferred prosecution agreement, under which Sandoz agreed to cooperate with the government's ongoing investigation.

The criminal admission matters because it is the one round where the company had to say "yes, we did this." Every settlement since then - the $265 million direct purchaser class in February 2024, the $275 million end purchaser class in December 2024, and now the $450 million state deal - has been structured as a civil release: money for closure, no new admissions. The total across all rounds is roughly $1.2 billion.

The odder part of the anatomy is the corporate timeline. Sandoz was part of Novartis until October 2023, when Novartis completed a spin-off that made Sandoz an independent public company. The alleged conduct - price-fixing across 31 generic medications - took place between May 2009 and December 2019. All of it happened while Sandoz was wearing the Novartis name.

So the entity paying $450 million today is legally the successor to the entity that committed the acts, but economically it is a different company, with different shareholders, different capital structure, and a different growth story. Novartis shareholders in 2013 did not own the Sandoz that is making payments in 2028. The people who will own Sandoz stock in 2030 are not the people who benefited from the inflated generic drug prices in 2015.

This is the gap between legal liability and economic consequence. Legally, the spin-off did not extinguish the obligation. Economically, the obligation landed on a much smaller company that inherited it along with the rest of the legacy business. Whether the market treats this as a fair transfer or a burden depends on whether you think Sandoz's current cash flow should price the sins of its former corporate parent.

Sandoz says the settlements "do not affect full-year 2026 guidance or the mid-term outlook" and that it has "increased its previously recognised provision to reflect the amounts required." That is the company's way of saying the hit is already marked on the balance sheet. The seven-year payment schedule means the cash outflow is manageable, not catastrophic.

This is not the only player in the machine. The multistate coalition, led by Connecticut, has been settling with defendants in batches. Earlier this year, Lannett Company paid $13.77 million and Bausch Health paid $4.08 million. Both had to cooperate with the states' ongoing case against remaining defendants - a requirement that could generate evidence against the 26+ companies still in the litigation. Other settlements include $13.1 million from Heritage Pharmaceuticals and $36 million from Apotex.

The cooperation clause is the structural hook that keeps the whole pipeline moving. Smaller defendants settle cheaply in exchange for helping build the case against the bigger ones. It is the same mechanic that prosecutors use in cartel cases: the first cooperator gets leniency, and the evidence flows downstream.

In this version, the downstream target has mostly been Sandoz, because it was one of the largest generic manufacturers and the DOJ's 2020 case established the facts. Now that the Sandoz state claims are resolved, the remaining defendants face a world where the biggest fish has already bought its way out of the net.

The simplest model is this: each category of buyer in the generic drug supply chain - the government, the wholesalers, the pharmacies, the insurers, the patients - is a different class, each with its own standing, its own damages theory, and its own settlement negotiation. The company does not settle once and walk away. It settles sequentially, because each class must be separately certified, separately negotiated, and separately approved by a court or a coalition of attorneys general.

So a company that admitted criminal antitrust violations in 2020 is still negotiating civil settlements in 2026. Not because the facts changed, but because the plaintiffs changed. Direct purchasers settled first. End purchasers came next. States followed. Indirect resellers are the latest tranche. It is less a resolution than an assembly line.

The machine is working as designed, in the sense that every group of harmed buyers has been compensated. But it also means the total bill grows with each round, because each settlement negotiates damages independently and the company cannot use an earlier payment to offset a later one. You pay the DOJ, then the direct purchasers, then the end purchasers, then the states, then the pharmacies - and each payment is a separate deal, not a pro-rata slice of a single pot.

The structural implication is that the cost of this kind of antitrust program is higher than any single settlement suggests. The $450 million headline number is one pipe on a rack of pipes. The total - roughly $1.2 billion - is the real metric. And the question for investors in Sandoz, or any other defendant still standing in the line, is not whether this round is expensive but whether there are rounds you have not seen yet.

For Sandoz, the answer appears to be no. Today's announcement closes the government and class-action books. The remaining exposure is opt-out individual plaintiffs - cases that tend to be small, fragmented, and difficult to aggregate into a meaningful aggregate threat. The seven-year payment schedule means the cash drag is modest and predictable.

For the states, the seven-year annuity is a liquidity promise from a mid-cap Swiss-listed company. That is worth examining if Sandoz's generic business deteriorates enough to make those payments sticky. But the payment structure itself is designed to survive normal business volatility - it is not a balloon, it is a stream.

The generic drug antitrust litigation was once a criminal prosecution. Now it is a series of civil annuities. The mechanism has not collapsed. It has just finished converting guilt into billing.